A Study to Evaluate Efficacy and Safety of Perampanel Administered as an Adjunctive Therapy in Pediatric Participants With Childhood Epilepsy
← catalyst calendarNCT04015141 · readout in 229 d
Sponsored by Eisai Inc. (industry) · 4523.T — their whole pipeline →.
Phase
Phase 2
Status
Active, not recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
100estimated
Sites
35
Countries
Belgium, Czechia, France +3
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2019-05-31 | actual | When the study began enrolling |
| Primary completion | 2027-04-06 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-12-23 | estimated | The whole study's end, after follow-up |
| First posted | 2019-07-10 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-10 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Pediatric Epileptic Syndrome
- Partial-onset Seizures
Interventions
- Drug: Perampanel Oral Suspension — also filed as E2007, Fycompa
- Drug: Perampanel Tablet — also filed as E2007, Fycompa
Primary outcome
what the primary-completion date above is the date OFProportion of 50% Responders For All Seizures During the Maintenance Period of Core Study
measured Week 10 to Week 23
Permalink · 4523.T's whole pipeline · Catalyst calendar · Every registered study · What changed